CLOSE X
IPL 2025
Mutual Fund
more from Mutual Fund
HomeMarketsMutual Fund MF UpdatesFund Card

Fund Card

GO

ITI Pharma & Healthcare Fund-Reg(G)

very highequitypharma & health care
16.11 0.14(0.85%) NAV as on 23 Apr 2025
1.47 % 1 M
20.52 % 1 Y
19.09 % 3 Y

Growth Chart of the Scheme vis a vis benchmark (SIP value 10,000)

  • 1M
  • 3M
  • 6M
  • 1Y
  • 3Y
  • 5Y
  • 10Y
  • max

FUND OBJECTIVE

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

SCHEME DETAILS

expense_ration-icon Expenses Ratio :

2.35

As on 31 Mar, 2025
age-icon Age :

3 yrs 5 m

Since 08 11 ,2021
exit_load Exit Load :

1%

aum AUM :

213.78 Crs

lock_in Lock-in :

1% on or before 12M, Nil after 12M

investing_style Investing Style :

Large Growth

Portfolio_book_value Portfolio Price To Book Value :

8.03

Min_Investment Min. Investment :

SIP 500 & Lumpsum 5000

Scheme_benchmark Scheme Benchmark :

NA

Fund_manager Fund Manager :

Rohan Korde,Dhimant Shah

LATEST ASSET & PORTFOLIO ALLOCATION

as on Mar 31 ,2025
Others 2.05 %
Equity 97.95 %

TOP HOLDINGS

Sun Pharmaceutical Industries...16.22 %
Divi's Laboratories Ltd.5.96 %
Lupin Ltd.5.78 %
Suven Pharmaceuticals Ltd.5.39 %
Apollo Hospitals Enterprise Ltd.5.16 %
See All Holding

ALLOCATION BY MARKET CAP

ALLOCATION BY SECTOR

Pharmaceuticals & Drugs74.88
Hospital & Healthcare Services18.70
Pesticides & Agrochemicals2.47
Chemicals0.98
Industrial Gases & Fuels0.92
See All Sectors

5-YEARS HISTORY

Financial Year2021-20222022-20232023-20242024-2025
NAV in Rs (as on 31-Mar-2025)9.528.9413.5315.64
Net Assets(Rs Crores) (as on 31-Mar-2025) 175.15 135.04 160.39 213.78
Scheme Returns(%)(Absolute)-4.83-6.0951.0514.23
B'mark Returns(%)(Absolute)NANANANA
Category Rank74/7564/7629/9013/102

RISKOMETER Level of Risk in the Scheme

Investors understand that their principal will be at very high risk

PERFORMANCE COMPARISON WITH SIMILAR SCHEMES

ITI Pharma & Healthcare Fund-Reg(G)Very HighEquity16.110.14(0.85%)NAV As on 23 Apr, 202508-Nov-2021Inception Date213.78AUM In Cr.20.52%1Y19.09%3YNA%5Y14.80%Since Inception
ICICI Pru Pharma Healthcare & Diagnostics (P.H.D) Fund-(G)Very HighEquity37.570.50(1.35%)NAV As on 23 Apr, 202513-Jul-2018Inception Date4,914.64AUM In Cr.24.40%1Y23.98%3Y25.65%5Y21.55%Since Inception
SBI Healthcare Opp Fund-Reg(G)Very HighEquity422.773.97(0.95%)NAV As on 23 Apr, 202514-Jul-1999Inception Date3,610.51AUM In Cr.24.04%1Y23.61%3Y25.30%5Y16.36%Since Inception
Tata India Pharma & Healthcare Fund-Reg(G)Very HighEquity29.620.35(1.19%)NAV As on 23 Apr, 202528-Dec-2015Inception Date1,183.65AUM In Cr.20.10%1Y20.07%3Y22.33%5Y12.35%Since Inception
corporate OFFICE Jhaveri Securities301/302 Payal Tower-II,Opp. M. S. University, Sayajigunj, Vadodara 390020.
CALL US 91-265-6161200/7161200
EMAIL US info@jhaveritrade.com
SEBI Reg. No. NSE, BSE, MCX : INZ000199232 Membership No.: NSE:08232, BSE:3015, MCX:56465 SEBI Regn.No. of DP : IN-DP-195-2016 (NSDL DPID:IN301991) AMFI: ARN-A3524 CIN of JSL: U67120GJ1992PLC018194 | GST : 24AAACJ4727A2Z4
COMPLIANCE OFFICER OFFICE
ATTENTION INVESTORS NSDL/CDSL KYC Advisory for investors
© CopyRights 2022, Jhaveri Securities All rights reserved.
Designed & Developed by Accord Fintech Pvt Ltd.